AstraZeneca (AZN) Given a $40.00 Price Target by BMO Capital Markets Analysts

AstraZeneca (NYSE:AZN) received a $40.00 price objective from investment analysts at BMO Capital Markets in a note issued to investors on Tuesday. The brokerage currently has a “buy” rating on the stock. BMO Capital Markets’ price objective suggests a potential upside of 18.24% from the company’s previous close.

A number of other analysts also recently weighed in on the company. Leerink Swann boosted their target price on AstraZeneca from $36.00 to $38.00 and gave the stock a “market perform” rating in a research report on Tuesday, February 6th. Sanford C. Bernstein boosted their target price on AstraZeneca from $40.00 to $42.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. ValuEngine upgraded AstraZeneca from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 3rd. Zacks Investment Research upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Monday, January 22nd. Finally, JPMorgan Chase & Co. upgraded AstraZeneca from a “neutral” rating to an “overweight” rating in a research report on Friday, December 29th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. AstraZeneca has an average rating of “Hold” and an average target price of $36.26.

Shares of AstraZeneca (NYSE:AZN) opened at $33.83 on Tuesday. The firm has a market capitalization of $84,210.00, a P/E ratio of 28.67, a P/E/G ratio of 2.05 and a beta of 0.74. AstraZeneca has a 12-month low of $28.43 and a 12-month high of $36.70. The company has a debt-to-equity ratio of 0.93, a current ratio of 0.80 and a quick ratio of 0.62.

AstraZeneca (NYSE:AZN) last released its earnings results on Friday, February 2nd. The company reported $1.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.44 by $0.86. The company had revenue of $5.78 billion during the quarter, compared to the consensus estimate of $5.49 billion. AstraZeneca had a return on equity of 34.74% and a net margin of 13.36%. AstraZeneca’s quarterly revenue was up 3.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.21 EPS. analysts expect that AstraZeneca will post 1.67 earnings per share for the current fiscal year.

A number of hedge funds have recently made changes to their positions in the business. Fisher Asset Management LLC lifted its position in AstraZeneca by 2.7% in the fourth quarter. Fisher Asset Management LLC now owns 11,917,332 shares of the company’s stock valued at $413,531,000 after purchasing an additional 315,759 shares during the last quarter. Wells Fargo & Company MN lifted its position in AstraZeneca by 7.6% in the third quarter. Wells Fargo & Company MN now owns 4,406,824 shares of the company’s stock valued at $149,303,000 after purchasing an additional 310,389 shares during the last quarter. Farallon Capital Management LLC lifted its position in AstraZeneca by 18.4% in the fourth quarter. Farallon Capital Management LLC now owns 3,765,000 shares of the company’s stock valued at $130,646,000 after purchasing an additional 585,000 shares during the last quarter. Ameriprise Financial Inc. lifted its position in AstraZeneca by 7.1% in the third quarter. Ameriprise Financial Inc. now owns 3,026,781 shares of the company’s stock valued at $102,643,000 after purchasing an additional 199,519 shares during the last quarter. Finally, Capital Bank & Trust Co lifted its position in AstraZeneca by 2.1% in the third quarter. Capital Bank & Trust Co now owns 2,730,208 shares of the company’s stock valued at $92,499,000 after purchasing an additional 57,353 shares during the last quarter. Hedge funds and other institutional investors own 14.91% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/02/22/astrazeneca-azn-given-a-40-00-price-target-by-bmo-capital-markets-analysts.html.

About AstraZeneca

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply